Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.152
Neutral
RSI(14)
48.449
Neutral
STOCH(KDJ)(9,3,3)
34.571
Sell
ATR(14)
0.590
High Vlolatility
CCI(14)
-90.998
Neutral
Williams %R
74.825
Sell
TRIX(12,20)
0.244
Sell
StochRSI(14)
9.631
Oversold
Search
Immatics NV
IMTXAdd to Watchlist
10.870USD
-0.300-2.69%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.49BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Immatics NV
Currency: USD Updated: 2026-05-15Key Insights
Immatics NV's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 67 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.52.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immatics NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Immatics NV Highlights
StrengthsRisks
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Growing
The company is in a growing phase, with the latest annual income totaling USD 41.58M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 41.58M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -14.38, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 101.84M shares, decreasing 14.61% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 748.03K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
18.520
Target Price
+65.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Immatics NV is 6.38, ranking 248 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 6.49M, representing a year-over-year decrease of 60.97%, while its net profit experienced a year-over-year decrease of 38.23%.
Score
Financials
9.26
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.52
Operational Efficiency
2.84
Growth Potential
5.21
Shareholder Returns
7.08
Immatics NV's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Immatics NV is 7.18, ranking 147 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -14.38, which is -471.21% below the recent high of 53.38 and -201.77% above the recent low of -43.40.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 67/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Immatics NV is 8.83, ranking 51 out of 382 in the Biotechnology & Medical Research industry. The average price target is 17.50, with a high of 25.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
18.520
Target Price
+65.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Immatics NV
IMTX
12
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Immatics NV is 6.65, ranking 196 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 11.70 and the support level at 10.27, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
11.152
Sell
MA10
11.187
Sell
MA20
11.199
Sell
MA50
10.512
Buy
MA100
10.210
Buy
MA200
9.308
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Immatics NV is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 75.94%, representing a quarter-over-quarter decrease of 1.92%. The largest institutional shareholder is Steven Cohen, holding a total of 1.75M shares, representing 1.31% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Immatics NV is 4.44, ranking 82 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.29
VaR
+5.09%
240-Day Maximum Drawdown
+27.80%
240-Day Volatility
+64.10%
Return
Best Daily Return
60 days
+6.17%
120 days
+14.80%
5 years
+27.46%
Worst Daily Return
60 days
-6.18%
120 days
-14.24%
5 years
-15.58%
Sharpe Ratio
60 days
+1.03
120 days
+0.47
5 years
+0.25
Risk Assessment
Maximum Drawdown
240 days
+27.80%
3 years
+74.05%
5 years
+77.36%
Return-to-Drawdown Ratio
240 days
+2.91
3 years
-0.03
5 years
-0.02
Skewness
240 days
+0.56
3 years
+0.63
5 years
+0.74
Volatility
Realised Volatility
240 days
+64.10%
5 years
+66.15%
Standardised True Range
240 days
+4.72%
5 years
+4.91%
Downside Risk-Adjusted Return
120 days
+74.52%
240 days
+74.52%
Maximum Daily Upside Volatility
60 days
+39.07%
Maximum Daily Downside Volatility
60 days
+34.16%
Liquidity
Average Turnover Rate
60 days
+0.39%
120 days
+0.39%
5 years
--
Turnover Deviation
20 days
-28.85%
60 days
-26.97%
120 days
-28.23%
Peer Comparison
Biotechnology & Medical Research
Immatics NV
IMTX
6.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
